A Safe, Orally Administered Agent for Dengue

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1117470

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Dengue virus is the most important mosquito-borne viral disease, with 2/3 of the world's population at risk. There is currently no treatment available for dengue. Our proposal aims to progress a safe and effective new treatment (4-HPR) against Dengue towards the clinic, generating all the required pharmacokinetic and pre-clinical animal data necessary to progress to a future clinical trial in humans. We will also investigate the use of 4-HPR as a dengue preventative.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Development Grants

Funding Amount: $857,659.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Virology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

dengue virus | flavivirus infection | infectious diseases | inhibitor design | therapeutic agents

Related Links